GlassScriptPhysician profile
Jay R Levinson
NPI 1275516692
$13,488.57
in general payments reported to CMS, 2019-2025
41 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $306 · 2021: $1,448 · 2022: $2,077 · 2023: $2,355 · 2024: $2,894 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,902.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,950.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,814.81 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,274.23 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $1,106.09 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $794.79 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $750.14 | 2019-2025 | |
| Gilead Sciences, INC. | $575.90 | 2019-2025 | |
| Genzyme Corporation | $568.21 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $392.65 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $361.96 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $269.36 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $243.05 | 2019-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $228.99 | 2021-2023 | |
| Lilly USA, LLC | $226.51 | 2024-2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $215.08 | 2023-2025 | Ibsrela |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $195.06 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $182.55 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $148.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $116.72 | 2022-2023 | Avsola, Amjevita |
| Sandoz INC. | $112.93 | 2023-2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $98.34 | 2022 | |
| Organon LLC | $97.96 | 2022-2025 | Hadlima, Renflexis |
| Qol Medical, LLC | $93.05 | 2019-2024 | Sucraid |
| Daiichi Sankyo INC. | $75.82 | 2019-2023 | Injectafer |
| Novo Nordisk INC | $69.72 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $68.83 | 2019-2023 | Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.83 | 2023-2024 | Cyltezo |
| Ucb, INC. | $50.22 | 2019 | |
| Fresenius Kabi USA, LLC | $48.74 | 2023 | |
| Celltrion USA INC. | $47.44 | 2025 | Vegzelma |
| Welch Allyn | $34.46 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $33.96 | 2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $33.26 | 2022 | |
| Evoke Pharma, INC. | $30.29 | 2025 | |
| Romark Laboratories, Lc | $22.27 | 2019 | |
| Mylan Institutional INC. | $20.96 | 2023 | Hulio |
| Shire North American Group INC | $15.42 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.17 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $15.03 | 2023 | Andexxa |
| Cook Medical LLC | $13.12 | 2021 | |
| Redhill Biopharma INC. | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.